去氨加压素对急诊科抗血小板治疗患者血肿扩大的影响
该多中心回顾性倾向匹配队列研究纳入11个美国急诊科2017年1月1日至2021年5月1日期间成人自发性脑出血且入院前使用抗血小板药的患者。共324例纳入,13.8%(n=45)接受去氨加压素,86.1%(n=279)未接受;倾向匹配后去氨加压素组35例对照140例。主要终点为24小时内良好或极好止血疗效,两组相似(去氨加压素组74.3% vs 对照组85%,差值-10.7% [-28.1%至6.7%]),次要结局无差异。去氨加压素组基线血肿体积显著更高(27.6 mL vs 2.1 mL)。作者结论提示不常规给予去氨加压素用于抗血小板相关脑出血,但需随机试验进一步研究。
要点
- 在11个美国急诊科的多中心回顾性倾向匹配队列中,抗血小板相关脑出血患者使用去氨加压素未改善24小时内良好或极好止血疗效(去氨加压素组74.3% vs 对照组85%,差值-10.7% [-28.1%至6.7%])。
- 去氨加压素组基线血肿体积显著高于对照组(27.6 mL vs 2.1 mL)。
- 倾向匹配后去氨加压素组35例、对照组140例,两组次要结局无差异。
- 作者结论提示不常规给予去氨加压素用于抗血小板相关脑出血,但需随机试验进一步研究。
适用人群与场景
- 成人患者≥18岁,主要诊断为自发性脑出血,且入院前使用抗血小板药,来自2017年1月1日至2021年5月1日期间11个参与EMPHARM-NET的美国急诊科。
研究设计与关键结果
- 研究类型:多中心、回顾性、倾向匹配队列研究,共11个美国急诊科参与EMPHARM-NET。
- 共评估1408例患者,最终纳入324例,其中13.8%(n=45)接受去氨加压素,86.1%(n=279)未接受。
- 倾向匹配后去氨加压素组35例,对照组140例。
- 去氨加压素组基线血肿体积显著高于对照组(27.6 mL vs 2.1 mL)。
- 主要终点良好或极好止血疗效两组相似:去氨加压素组74.3% vs 对照组85%,差值-10.7% [-28.1%至6.7%]。
- 次要结局无差异。
证据类型、等级与局限
- 证据类型:多中心回顾性倾向匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论提示不常规给予去氨加压素用于抗血小板相关脑出血,但需随机试验进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Current guidelines state the effectiveness of desmopressin to reduce hematoma expansion in antiplatelet-related intracerebral hemorrhage (ICH) is uncertain. This study sought to determine if desmopressin decreased hematoma expansion in ICH patients on antiplatelet agents.
METHODS: We conducted a multi-center, retrospective propensity-matched cohort study at 11 US emergency departments (ED) that participate in EMPHARM-NET. Adult patients ≥18 years with a primary diagnosis of spontaneous ICH on antiplatelets prior to admission from January 1, 2017 through May 1, 2021 were included. The primary endpoint was good or excellent hemostatic efficacy within the first 24 h following ICH between patients that did and did not receive desmopressin. Brain imaging was reviewed using 3D-Slicer by blinded expert physicians.
RESULTS: Overall, 1408 patients were evaluated for inclusion. A total of 324 patients were included, of which 13.8 % (n = 45) received desmopressin and 86.1 % (n = 279) did not. After propensity matching, 35 patients receive desmopressin compared to 140 controls. Baseline hematoma volume (27.6 mL vs. 2.1 mL) and was significantly higher in the desmopressin group. The primary endpoint of good or excellent hemostatic efficacy was similar between groups (74.3 % desmopressin group vs. 85 % control group, -10.7 % [-28.1 % to 6.7 %]). There was no difference in secondary outcomes.
CONCLUSION: In this multicenter cohort, patients receiving desmopressin had higher baseline intraparenchymal hematoma volume, and did not appear to result in improved hemostatic efficacy relative to the control group. These results suggest against routine administration of desmopressin for antiplatelet-related ICH, though future study in a randomized trial design is necessary.
参考来源
- Rech MA, Brown C, Slocum GW, et al. Impact of desmopressin on hematoma expansion in patients presenting to the emergency department on antiplatelet therapy. Am J Emerg Med. 2025. PMID: 40186945. doi:10.1016/j.ajem.2025.03.052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。